Composition for preventing or improving hair loss comprising dungeon as an effective ingredient
阅读说明：本技术 用于预防或改善脱发的包含有效成分董尼酮的组合物 (Composition for preventing or improving hair loss comprising dungeon as an effective ingredient ) 是由 苏弘燮 金亨珍 迪本德拉·卡德卡 吴奇洙 李承勋 于 2019-01-18 设计创作，主要内容包括：本发明涉及用于预防或改善化疗诱发的脱发的药物组合物,该药物组合物包含作为活性成分的董尼酮化合物、其药学上可接受的盐、其前药、其溶剂化物或其异构体。将本发明的董尼酮化合物给药至由给药抗癌药物所诱发的脱发的动物模型,结果观察到脱发以及毛囊和内根鞘的消除减少了。因此,董尼酮化合物、其药学上可接受的盐、其前药、其溶剂化物或其异构体可以有效地用在用于预防或改善由抗癌疗法引起的脱发的药物组合物中。(The present invention relates to a pharmaceutical composition for preventing or ameliorating chemotherapy-induced alopecia, which comprises a dungeon compound, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or an isomer thereof, as an active ingredient. Administration of the dungeon compound of the present invention to an animal model of hair loss induced by administration of anticancer drugs resulted in the observation that hair loss and elimination of hair follicles and inner root sheaths were reduced. Accordingly, the dungeon compound, its pharmaceutically acceptable salt, its prodrug, its solvate or its isomer can be effectively used in a pharmaceutical composition for preventing or improving alopecia caused by anticancer therapy.)
1. A pharmaceutical composition for preventing or improving hair loss, comprising as active ingredients:
a compound represented by formula 1, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or an isomer thereof:
[ formula 1]
2. The pharmaceutical composition of claim 1, wherein the alopecia is caused by treatment with an anti-cancer drug.
3. The pharmaceutical composition of claim 2, wherein the anticancer drug is at least one selected from the group consisting of doxorubicin, amsacrine, bleomycin, busulfan, cyclophosphamide, cytarabine, daunomycin, docetaxel, epirubicin, etoposide, 5-fluorouracil, gemcitabine, ifosfamide, irinotecan, lomustine, melphalan, paclitaxel, thiotepa, topotecan, vinblastine, vindesine, and vinorelbine.
4. The pharmaceutical composition of claim 1, wherein the compound is dependent on the enzyme NAD (P) H: quinone oxidoreductase 1(NQO 1).
5. The pharmaceutical composition of claim 1, wherein the compound prevents degradation of the hair follicle and inner root sheath.
6. A composition for promoting hair growth, comprising as active ingredients:
a compound represented by formula 1, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or an isomer thereof:
[ formula 1]
7. Use of the pharmaceutical composition according to claim 1 for preventing or ameliorating hair loss.
8. Use of the pharmaceutical composition of claim 1 for the preparation of a medicament for preventing or treating hair loss.
9. A method for preventing or ameliorating hair loss comprising the steps of: administering a pharmaceutical composition according to claim 1.
Technical Field
The present invention relates to a pharmaceutical composition for preventing or improving hair loss, which comprises a dungeon compound, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or an isomer thereof as an active ingredient.
Background
Cancer is one of the health and life threatening diseases of human beings, and its incidence rate is always increasing. Methods of cancer treatment include surgery, radiation therapy, biotherapy, chemotherapy, and the like. Among them, anticancer drugs used in chemotherapy exhibit cytotoxicity to cancer cells in such a manner that they intervene in metabolic pathways of cancer cells and directly interact with DNA, thereby blocking replication, transcription and translation processes of DNA or interfering with synthesis of nucleic acid precursors, and inhibiting cell division.
However, cancer patients have many adverse effects on chemotherapy, such as anemia and cytopenia caused by bone marrow suppression, gastrointestinal disorders (including nausea, vomiting, diarrhea, etc.), and alopecia. Approximately 65% to 70% of cancer patients experience chemotherapy-induced alopecia (CIA), which is known to be one of the most psychologically impacting adverse reactions for patients. In addition, CIA can cause a change in appearance, thereby giving psychological impact to the patient. Moreover, CIA can cause embarrassment, sadness, disgust, anger, frustration, etc. to the patient, which can result in a loss of confidence or sexual appeal.
In particular, hair loss makes patients aware of cancer diseases and suffers from negative mood swings. In addition, hair loss together with psychological flinching can lead to difficulties in interpersonal relationships that not only cause physical and mental distress, but ultimately can negatively impact the quality of life. This hair loss is particularly severe in women. It has been reported that alopecia is considered the most serious adverse effect of chemotherapy in 47% of female Cancer patients, and that about 8% of patients refuse to receive chemotherapy because of fear of alopecia (McGarveyEL et al, Cancer practice, 2001; 9: 283-. In addition, studies have shown that negative psychological effects of CIA may suppress immune function in patients and cause cancer progression (Spiegel D et al, Biol Psychiatry, 2003; 54: 269-282).
The incidence and extent of CIA varies depending on the type, half-life, dose, route of administration, rate of administration and dosing regimen of the anticancer drug. However, it is known that many anticancer drugs used in chemotherapy cause CIA. In particular, anticancer drugs that often cause CIA include doxorubicin, cyclophosphamide, docetaxel, daunomycin, epirubicin, etoposide, ifosfamide, irinotecan, paclitaxel, topotecan, vindesine, and vinorelbine. In addition, anticancer drugs known to cause CIA in some cases include amsacrine, bleomycin, busulfan, cytarabine, 5-fluorouracil, gemcitabine, lomustine, melphalan, thiotepa, vinblastine, and the like (Trueb RM., Skin Therapy Lett., 2010; 15(7): 5-7).
In particular, it has been reported that an antimicrotubule agent (e.g., paclitaxel) causes CIA in 80% or more of patients, a topoisomerase inhibitor (e.g., doxorubicin) causes CIA in 60% to 100% of patients, an alkylating agent (including cyclophosphamide) causes CIA in 60% or more of patients, an antimetabolite agent (e.g., 5-fluorouracil) causes CIA in 10% to 50% of patients, and CIA occurs more frequently and more seriously in the case of combined administration of two or more anticancer drugs than in the case of administration of a single drug (Batchelor D., Eur J Cancer Care, 2001; 10: 147-. Although chemotherapy-induced alopecia (CIA) is a serious side effect that affects not only individual patients but also the whole society, no effective treatment has been available so far.
On the other hand, dungeon is a naphthoquinone-based compound classified into two structures: alpha-Dongnione (2, 3-dihydro-2, 3, 3-trimethylnaphtho [1,2-b ]]Furan-4, 9-dione) and duninone (2, 3-dihydro-2, 3, 3-trimethylnaphtho [1, 2-b)]Furan-4, 5-dione).Furthermore, dunonide is obtained from the leaves of chicory dunnii (streptacarpussdunnii) native to south america or some kind of Typha latifolia (calcelaria). With respect to the pharmacological effects of dungeon, the following have been reported so far: dongninone increases the activity of the enzyme NAD (P) H: quinone oxidoreductase 1(NQO1), resulting in intracellular NAD+Etc. to allow deacetylases (e.g., using such NAD)+Sirtuin 1) and the like as a coenzyme are activated, which makes dunniadone effective for the prevention and treatment of small intestinal mucosal damage caused by anticancer drugs, acute pancreatitis caused by alcohol or gall stones in pancreatic ducts, and the like (Pandit et al, Biochem biophysis Res commu, 2015; 467: 697-; shen et al, Sci Rep, 2017; 7:3006). In addition, U.S. Pat. No. 9,066,922B2 discloses that dungeon is useful for the prevention and treatment of obesity, diabetes, metabolic syndrome, neurodegenerative diseases and diseases associated with mitochondrial dysfunction.
Disclosure of Invention
Technical problem
As a result of an effort to find a substance effective for improving chemotherapy-induced alopecia, the present inventors have determined that dungeon, which has been conventionally used as a substrate for the enzyme NQO1, can improve alopecia caused by anticancer drugs administered singly or in combination, and thus completed the present invention.
Technical scheme
In order to achieve the above objects, in one aspect of the present invention, there is provided a pharmaceutical composition for preventing or improving hair loss, comprising a compound represented by
[ formula 1]
In another aspect of the present invention, there is provided a composition for promoting hair growth, comprising a compound represented by
[ formula 1]
In yet another aspect of the present invention, there is provided a use of the pharmaceutical composition of the present invention for preventing or ameliorating hair loss.
In yet another aspect of the present invention, there is provided a use of the pharmaceutical composition of the present invention for the preparation of a medicament for preventing or treating alopecia.
In yet another aspect of the present invention, there is provided a method for preventing or ameliorating hair loss, comprising the step of administering the pharmaceutical composition of the present invention.
Advantageous effects
In the present invention, a naphthoquinone-based compound, dungeon, is administered to an animal model having alopecia caused by the administration of cyclophosphamide alone or to an animal model having alopecia caused by the combined administration of docetaxel, doxorubicin, and cyclophosphamide. As a result, it was confirmed that hair loss was suppressed and the decline of hair follicle and inner root sheath was prevented in such animal model. Therefore, the dungeon compound, its pharmaceutically acceptable salt, its prodrug, its solvate or its isomer can be effectively used in a pharmaceutical composition for preventing or ameliorating chemotherapy-induced alopecia.
Drawings
Fig. 1 shows an experimental plan for confirming the hair loss inhibitory effect of dungeon in an animal model having alopecia caused by cyclophosphamide.
Fig. 2a shows the results obtained by photographing the skin surface of each experimental group on day 8 after hair removal in an animal model with alopecia caused by cyclophosphamide: g1: control (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + dunaidone (cyclophosphamide plus dunaidone combination treatment group); g4: dungeon (group treated alone).
Fig. 2b shows the results obtained by photographing the skin surface of each experimental group on day 12 after hair removal in an animal model with alopecia caused by cyclophosphamide: g1: control (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + dunaidone (cyclophosphamide plus dunaidone combination treatment group); g4: dungeon (group treated alone).
Fig. 3a shows the results obtained by photographing the skin surface of each experimental group on day 14 after hair removal in an animal model with alopecia caused by cyclophosphamide: g1: control (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + dunaidone (cyclophosphamide plus dunaidone combination treatment group); g4: dungeon (group treated alone).
Fig. 3b shows the results obtained by photographing the skin surface of each experimental group on day 16 after hair removal in an animal model with alopecia caused by cyclophosphamide: g1: control (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + dunaidone (cyclophosphamide plus dunaidone combination treatment group); g4: dungeon (group treated alone).
Fig. 3c shows the results obtained by photographing the skin surface of each experimental group on day 18 after hair removal in an animal model with alopecia caused by cyclophosphamide: g1: control (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + dunaidone (cyclophosphamide plus dunaidone combination treatment group); g4: dungeon (group treated alone).
Fig. 4 shows the results obtained by observing the skin surface of mice with an optical microscope on day 18 after hair removal in an animal model with alopecia caused by cyclophosphamide: g1: ctrl (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + Dun (cyclophosphamide plus donitrone combination group); g4: dun (Dun alone treated group).
Fig. 5a shows the results obtained by photographing the skin surface of each experimental group on day 12 after hair removal in NQO1 knockout mice: g1: ctrl (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + Dun (cyclophosphamide plus donitrone combination group); g4: dun (Dun alone treated group).
Fig. 5b shows the results obtained by photographing the skin surface of each experimental group on day 14 after hair removal in NQO1 knockout mice: g1: ctrl (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + Dun (cyclophosphamide plus donitrone combination group); g4: dun (Dun alone treated group).
Fig. 6a shows the results obtained by photographing the skin surface of each experimental group on day 16 after hair removal in NQO1 knockout mice: g1: ctrl (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + Dun (cyclophosphamide plus donitrone combination group); g4: dun (Dun alone treated group).
Fig. 6b shows the results obtained by photographing the skin surface of each experimental group on day 18 after hair removal in NQO1 knockout mice: g1: ctrl (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + Dun (cyclophosphamide plus donitrone combination group); g4: dun (Dun alone treated group).
Fig. 7 shows the results obtained by observing the skin surface of a mouse with an optical microscope on day 18 after hair removal in NQO1 knockout mice: g1: ctrl (PBS treated group); g2: CYP (cyclophosphamide treated group); g3: CYP + Dun (cyclophosphamide plus donitrone combination group); g4: dun (Dun alone treated group).
FIG. 8a shows a graph showing NAD in skin tissue with and without treatment with dunniatone in an animal model with alopecia caused by cyclophosphamide +Concentrations (# p < 0.05: comparison between normal and cyclophosphamide groups, # p < 0.05: comparison between cyclophosphamide and cyclophosphamide + dunnitone combination).
FIG. 8b shows a graph showing NADH concentration in skin tissue with and without treatment with duntonine in an animal model with alopecia caused by cyclophosphamide ([ p ] 0.05: comparison between normal group and cyclophosphamide group).
FIG. 8c is a graph showing NAD in skin tissue with and without treatment with dunniatone in an animal model with alopecia caused by cyclophosphamide+the/NADH ratio (# p < 0.05: comparison between the normal group and the cyclophosphamide group, # p < 0.05: comparison between the cyclophosphamide group and the cyclophosphamide + dunanone combination treatment group).
FIG. 8d shows a graph showing Sirt1 activity in skin tissue with and without granidone treatment in an animal model with alopecia caused by cyclophosphamide (# p < 0.05: compared between normal and cyclophosphamide groups, # p < 0.05: compared between cyclophosphamide and cyclophosphamide + granidone combination treatment groups).
Fig. 9 shows a graph showing the effect of dungeon on the expression of Sirt1 protein and acetylation of p65 and p53 proteins in skin tissues in an animal model with alopecia caused by cyclophosphamide.
Fig. 10 shows an experimental plan for confirming the hair loss inhibitory effect of dungeon in an animal model having alopecia caused by docetaxel, doxorubicin and cyclophosphamide.
Fig. 11a shows the results obtained by photographing the skin surface of each experimental group on day 12 after hair removal in an animal model with alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dungeon (group treated alone).
Fig. 11b shows the results obtained by photographing the skin surface of each experimental group on the 14 th day after hair removal in the animal model with alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dungeon (group treated alone).
Fig. 12a shows the results obtained by photographing the skin surface of each experimental group on day 16 after hair removal in an animal model with alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dungeon (group treated alone).
Fig. 12b shows the results obtained by photographing the skin surface of each experimental group on day 18 after hair removal in an animal model with alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dungeon (group treated alone).
Fig. 13 shows the results obtained by observing the skin surface of the mouse with an optical microscope on the 18 th day after hair removal in an animal model with alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dungeon (group treated alone).
Fig. 14 shows an experimental plan for confirming hair loss inhibitory effect of dungeon in an animal model with NQO1 knockout of alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dongninone (group treated with Dongnione alone (20 mg/kg)).
Fig. 15 shows the results obtained by photographing the skin surface of mice on days 8, 12, 14, 16 and 18 after hair removal in an animal model with NQO1 knockdown of alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dungeon (group treated alone).
Fig. 16 shows the results obtained by observing the skin surface of mice with an optical microscope at day 18 after hair removal in an animal model with NQO1 knockdown of alopecia caused by docetaxel, doxorubicin and cyclophosphamide: g1: control (PBS treated group); g2: 6 XTAC (docetaxel (11.58mg/kg), doxorubicin (9.24mg/kg) and cyclophosphamide (76.8 mg/kg)); g3: 6X TAC + dunanone (group of 6X TAC plus dunanone combination therapy); g4: dungeon (group treated alone).
Detailed Description
Hereinafter, the present invention will be described in detail.
In one aspect of the present invention, there is provided a pharmaceutical composition for preventing or improving hair loss, comprising a compound represented by
[ formula 1]
As used herein, the term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not cause significant irritation to the organism to which it is administered and does not abrogate the biological activity and properties of the compound. Pharmaceutically acceptable salts include acid addition salts formed with acids such as inorganic acids (e.g., hydrochloric, sulfuric, nitric, phosphoric, hydrobromic, hydroiodic, and the like), organic carbonic acids (e.g., tartaric, formic, citric, acetic, trichloroacetic, trifluoroacetic, gluconic, benzoic, lactic, fumaric, maleic, salicylic, and the like), and sulfonic acids (e.g., methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, and the like), which form non-toxic acid addition salts containing pharmaceutically acceptable anions. For example, pharmaceutically acceptable salts of carboxylic acids include metal or alkaline earth metal salts formed from lithium, sodium, potassium, calcium, magnesium, and the like, salts of amino acids (e.g., lysine, arginine, and guanidine), and organic salts (e.g., dicyclohexylamine, N-methyl-D-glucosamine, tris (hydroxymethyl) methylamine, diethanolamine, choline, and triethylamine). The compound represented by
As used herein, the term "prodrug" refers to an agent that is converted in vivo to the parent drug. Prodrugs are often used because they are easier to administer than the parent drug. For example, such prodrugs can be bioavailable by oral administration, whereas the parent drug may not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. For example, a prodrug may be a compound that is administered as an ester (prodrug) to facilitate its transport across the cell membrane where water solubility is detrimental to migration, but is metabolically hydrolyzed to the carboxylic acid as the active species once inside the cell where water solubility is beneficial. Another example of a prodrug may be a short peptide (polyamino acid) bonded to an acidic group where the peptide is metabolized to reveal the active moiety.
As used herein, the term "solvate" refers to a compound of the invention or a salt thereof that further comprises a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Thus, preferred solvents are those that are volatile, non-toxic, and/or acceptable for administration to a human. In case the solvent is water, the solvate refers to a hydrate.
As used herein, the term "isomer" refers to a compound of the present invention or a salt thereof having the same chemical formula or molecular formula, but being optically or spatially different.
Hereinafter, unless otherwise specified, the term "compound represented by
The pharmaceutical composition may be administered in a therapeutically effective amount. As used herein, the term "therapeutically effective amount" refers to an amount of a compound (active ingredient) administered that is effective to alleviate or reduce to some extent one or more symptoms of a disorder in need of treatment or to delay the onset of symptoms or clinical signs of a disease in need of prevention. Thus, a therapeutically effective amount refers to an amount that has the following effects: (i) reversing the rate of progression of the disease, (ii) to some extent arresting further development of the disease, and/or (iii) to some extent alleviating (preferably eliminating) one or more symptoms associated with the disease. A therapeutically effective amount can be determined empirically by experimentation with the compound in known in vivo and in vitro model systems for the disease to be treated.
A pharmaceutical composition comprising the dungeon compound, its pharmaceutically acceptable salt, its prodrug, its solvate, or its isomer of the present invention as an active ingredient can be formulated for oral administration and administered orally. Formulations for oral administration include, for example, tablets, pills, hard/soft capsules, liquids, suspensions, emulsifiers, syrups, granules, elixirs and the like, and these formulations contain, in addition to the active ingredient, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine) and lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and/or polyethylene glycol). Tablets may also contain binders such as magnesium aluminium silicate, starch paste, gelatin, methyl cellulose, sodium carboxymethyl cellulose and/or polyvinylpyrrolidone and, if desired, disintegrating agents (such as starch, agarose and alginic acid or its sodium salt), or boiling mixtures and/or adsorbents, colouring, flavouring and sweetening agents.
A pharmaceutical composition comprising the dungeon compound, its pharmaceutically acceptable salt, its prodrug, its solvate, or its isomer of the present invention as an active ingredient can be administered parenterally, which can be performed by subcutaneous injection, intravenous injection, intramuscular injection, or intrapleural injection. Here, in the case of a formulation formulated for parenteral administration, a pharmaceutical composition comprising the dungeon compound of the present invention, its pharmaceutically acceptable salt, its prodrug, its solvate, or its isomer as an active ingredient may be mixed with a stabilizer or a buffer in water to form a solution or a suspension, and then the solution or suspension may be prepared into a unit-dose ampoule or vial. The compositions may be sterile and/or may further comprise preservatives, stabilisers, hydrating or emulsifying agents, adjuvants (e.g. salts and/or buffers for regulating osmotic pressure) and other therapeutically useful substances. The compositions may be formulated by conventional means, for example by mixing, granulating or coating.
In addition, the human dose of the composition of the present invention may vary depending on the age, body weight, sex, dosage form, health condition and severity of disease of a patient. The dose is usually 0.001 mg/day to 2,000 mg/day, and preferably 0.01 mg/day to 1,000 mg/day, based on an adult patient having a body weight of 60 kg; and the dosage may be administered once to several times per day at regular intervals, as appropriate by a physician or pharmacist. The pharmaceutical composition according to the present invention comprises from about 0.01% to 100% by weight of a dungeon compound; however, the amount may vary depending on the dosage form.
Alopecia can be due to genetic causes, hormones, autoimmune diseases, stress, nutritional deficiencies, use of drugs, childbirth, fever, surgery, and the like. In particular, the alopecia may be alopecia caused by the use of a medicament, and preferably may be chemotherapy-induced alopecia.
Chemotherapy may be administered by administering a single anticancer drug or by administering two or more anticancer drugs in combination. In the case of combined administration, two or more anticancer drugs may be administered at time intervals.
Anti-cancer drugs may include, but are not limited to, conventional anti-cancer drugs or targeted anti-cancer drugs that attack only cancer cells by molecular targets specific to the respective cancer type (where the growth and metastasis of the cancer is caused by the activity of specific molecules involved in cancer growth and carcinogenesis).
The conventional anticancer drug may be at least one selected from the group consisting of adriamycin, amsacrine, bleomycin, busulfan, cyclophosphamide, cytarabine, daunomycin, docetaxel, epirubicin, etoposide, 5-fluorouracil, gemcitabine, ifosfamide, irinotecan, lomustine, melphalan, paclitaxel, thiotepa, topotecan, vinblastine, vindesine and vinorelbine, and preferably may be at least one selected from the group consisting of docetaxel, adriamycin and cyclophosphamide.
The compounds may be dependent on the enzyme NAD (P) H: quinone oxidoreductase 1(NQO 1).
The compound can prevent the deterioration of hair follicle and inner root sheath.
In a specific embodiment of the invention, the inventors established an animal model with chemotherapy-induced alopecia by a single intraperitoneal injection of cyclophosphamide into C57BL/6 mice. Donthone was orally administered to the animal model daily, starting three days prior to the administration of cyclophosphamide. As a result, it was confirmed that the cyclophosphamide plus donitrone combination-treated group exhibited inhibition of hair loss (fig. 2a to 3c), prevention of deterioration of hair follicles and inner root sheaths in skin tissues, and an increase in the number of hairs (fig. 4) as compared with the cyclophosphamide-treated group alone.
In addition, to confirm whether the hair loss inhibitory effect of dungeon is mediated by the enzyme nad (p) H: quinone oxidoreductase 1(NQO1), the present inventors established an animal model of NQO1 knockout with chemotherapy-induced alopecia by a single intraperitoneal injection of cyclophosphamide into NQO1 knockout mice. Donthone was orally administered to the animal model daily, starting three days prior to the administration of cyclophosphamide. As a result, it was confirmed by visual examination that unlike the results observed with C57BL/6 mice, the cyclophosphamide-and-dunonione combination-treated group exhibited the progress of hair loss to a level similar to that of the cyclophosphamide-treated group alone (fig. 5a to 6 b); and it was confirmed that in the group of cyclophosphamide plus dungeon combination treatment, the decline of the hair follicle and the inner root sheath in the skin tissue occurred (fig. 7).
In addition, to confirm whether DOWN causes NAD+The increase in concentration and the increase in the activity of the enzyme Sirt1, the inventors analyzed the presence of cyclophosphamideNAD in skin tissue obtained on day 18 after hair removal in a mouse model of induced alopecia+Concentration and NADH concentration and NAD+the/NADH ratio. As a result, it was observed that dungeon increased the expression level of Sirt1 protein, NAD, which had been reduced by cyclophosphamide +Concentration and NAD+Phenomenon of/NADH ratio (FIGS. 8a to 8 c); and it was confirmed that NAD was used in the group of cyclophosphamide plus duninone combination therapy+The activity of Sirt1 protein as substrate was maintained at a level similar to that of the normal group (fig. 8 d). Furthermore, a phenomenon was observed that, although cyclophosphamide had resulted in a decrease in the expression of Sirt1 protein and an increase in acetylation of the target proteins NF- κ B p65 and p53 in skin tissue, combination treatment with dungeon normalized Sirt1 expression and inhibited acetylation of p65 and p53 (fig. 9).
In addition, the present inventors established an animal model with chemotherapy-induced alopecia by combined administration of docetaxel, doxorubicin and cyclophosphamide (hereinafter referred to as TAC) into C57BL/6 mice. Donthone was administered to the animal model daily starting three days prior to administration of TAC. As a result, it was confirmed that the group treated with TAC plus dungeon exhibited inhibition of hair loss (fig. 11a to 12b), prevention of deterioration of hair follicles and inner root sheaths in skin tissues, and an increase in the number of hairs (fig. 13) as compared with the group treated with TAC alone.
To confirm whether the hair loss inhibitory effect of dungeon is mediated by the enzyme nad (p) H: quinone oxidoreductase 1(NQO1), the present inventors established an animal model of NQO1 knockout with chemotherapy-induced alopecia by intraperitoneal injection of TAC, a combination anticancer drug, into NQO1 knockout mice (fig. 14). Donerone was orally administered to the animal model daily, starting three days prior to administration of TAC. As a result, it was confirmed by visual examination that the group treated with TAC plus dungeon exhibited the progress of hair loss to a level similar to that of the group treated with TAC alone, unlike the results observed with C57BL/6 mice (fig. 15); and it was confirmed that in the group treated with TAC plus dungeon in combination, the decline of the hair follicle and the inner root sheath in the skin tissue occurred (fig. 16).
From these results, it was confirmed that the dungeon compound of the present invention inhibits hair loss and prevents the regression of hair follicles and inner root sheaths in a NQO 1-dependent manner in animal models having hair loss caused by the administration of cyclophosphamide alone or in animal models having hair loss caused by the combined administration of docetaxel, doxorubicin and cyclophosphamide. Accordingly, the duninone compound, its pharmaceutically acceptable salt, its prodrug, its solvate or its isomer of the present invention can be effectively used as an active ingredient in a pharmaceutical composition for preventing or improving chemotherapy-induced alopecia.
In another aspect of the present invention, there is provided a composition for promoting hair growth, comprising a compound represented by
[ formula 1]
In yet another aspect of the present invention, there is provided a use of the pharmaceutical composition of the present invention for preventing or ameliorating hair loss.
In yet another aspect of the present invention, there is provided a use of the pharmaceutical composition of the present invention for the preparation of a medicament for preventing or treating alopecia.
In yet another aspect of the present invention, there is provided a method for preventing or ameliorating hair loss, comprising the step of administering the pharmaceutical composition of the present invention.
Modes for carrying out the invention
Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are given only for explaining the present invention, and the scope of the present invention is not limited by the following examples.
- 上一篇：一种医用注射器针头装配设备
- 下一篇：GCN2抑制剂及其用途